A Phase 2/3 interventional study of Codabakalner and Placebo in Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD), sponsored by Spinogenix. Not yet recruiting. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Spinogenix · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Study to Investigate the Effects and Safety of Codabakalner for the Treatment of Fragile X Syndrome in Male Participants and Adult Participants with Autism Spectrum Disorders
This Phase 2b/3, randomized, double-blind, placebo-controlled, 2-part study will evaluate the efficacy, safety and tolerability of different dose regimens of codabakalner in adult male participants with Fragile X syndrome. The results from Phase 2b will be hypothesis generating and will inform the Phase 3 design.
Phase 2b, dose-regimen finding, 4-arm parallel design: Eligible participants will be randomized 1:1:1:1 to receive codabakalner at different doses or matched placebo. Participants will receive study intervention over 4 weeks and will be followed up for 4 weeks after last dose of study intervention.
Phase 3, 2-arm parallel design: Eligible participants will be randomized 1:1 to receive codabakalner or matched placebo. The dose of codabakalner administered in the Phase 3 will be defined based on analysis of Phase 2b. Participants will receive study intervention over 12 weeks and will be followed up for 4 weeks after last dose of study intervention.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
This study's planned enrollment of 120 is above the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Browse Fragile X Syndrome studies →Spinogenix is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 2b: Participants with FXS or ASD will be randomized to receive a daily dose of codabakalner daily for 4 weeks
Drug: Codabakalner
Participants with FXS or ASD will be randomized to receive a daily dose of placebo over 4 weeks.
Drug: Placebo
Participants with FXS will be randomized to receive a daily dose of codabakalner determined from Phase 2b over 12 weeks
Drug: Codabakalner
Participants with FXS will be randomized to receive a daily dose of placebo for 12 weeks
Drug: Placebo
synthetic small molecule
Also known as: SPG601
Placebo
Phase 2b: FXS- Change from baseline in Total Cognition Composite Change Sensitive Score from the NIH-TCB
The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.
Time frame: 28 days
Phase 2b: ASD - Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales in ASD(Vineland-III) Adaptive Behavior Composite Score
Vineland Adaptive Behavior Composite (ABC) have a mean of 100 and a standard deviation of 15, where scores from 85 to 115 reflect expected or average adaptive functioning
Time frame: 28 days
Phase 3: FXS - Change from baseline in Total Cognition Composite score from the NIH-TCB
The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning.
Time frame: 12 weeks
Phase 2b: FXS- Change from baseline in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCB
The Fluid Cognition Composite (FCC) from the NIH Toolbox Cognition Battery (NIHTB-CB) is designed to measure changes to neurological functioning. It combines scores from five tests (Dimensional Change Card Sort, Flanker, List Sorting, Pattern Comparison, and Picture Sequence Memory) to provide a measure of executive function, memory, and processing speed. Higher scores indicate higher level of functioning. Superior ability is 130, average is approx. 100 and less than 70 is impairment.
Time frame: 28 days
Phase 2b: FXS- Change from baseline in Flanker Scores from the NIH-TCB
The Flanker test measures executive attention, inhibitory control, and attention by having participants identify the direction of a central arrow (or fish for young children) while ignoring surrounding flanking stimuli. Yields a standardized score scaled with a mean of 100 and a standard deviation of 15 (up to a maximum score of 130)
Time frame: 28 days
Phase 2b- FXS Change from Baseline at Day 28 on the Vineland Adaptive Behavior Scales (Vineland-III) Adaptive Behavior Composite Score
Vineland Adaptive Behavior Composite (ABC) have a mean of 100 and a standard deviation of 15, where scores from 85 to 115 reflect expected or average adaptive functioning
Time frame: 28 days
Phase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of severity (CGI-S) as assessed by the investigator
This is a 7-point clinician-rated tool used to measure how ill a patient is at the time of assessment
Time frame: 28 days
Phase 2b: FXS and ASD: Change from baseline at Day 28 in Clinical global impression of improvement as assessed by the investigator
The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale used to assess treatment response. The score ranges from 1 to 7 (with 1 being "very much improved", 4 being "no change" to 7 being "very much worse")
Time frame: 28 days
Phase 2b: FXS and ASD: Change from baseline at Day 28 in Caregiver global impression of change (CGI-C) as assessed by the caregiver
The Caregiver Global Impression of Improvement (CGI-C) is a global measure to provide a caregiver's perspective of a subject's overall condition. The caregiver will use a 7-point scale to assess how the condition has changed from baseline. A higher number indicates worsening condition.
Time frame: 28 days
Phase 2b: FXS and ASD: Change from baseline at Day 28 in the Numerical Rating Scale as completed by the caregiver
Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'
Time frame: 28 days
Phase 2b: FXS and ASD - Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 28 days
Phase 2b: FXS and ASD - Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study
Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. Range is 2-25
Time frame: 28 days
Phase 2b: FXS and ASD - The PK parameters of codabakalner concentrations in plasma-Cmax
Maximum concentration of drug in plasma following dose
Time frame: 28 days
Phase 2b: FXS and ASD: Change from baseline to Day 28 in EEG resting state relative power in the alpha, theta, and gamma bands during rest
EEG power bands categorize brain electrical activity into five primary frequency ranges that reflect different states of arousal, sleep, and cognition
Time frame: 28 days
Phase 3: Change from baseline to week 12 in Total Cognition Composite score from the NIH-TCB
The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.
Time frame: 12 weeks
Phase 3: Incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs)
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 12 weeks
Phase 3: Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study
Prospective suicidality assessment is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS), a questionnaire to evaluate suicidal ideation and behavior. Answer "yes" on item 4 or 5 of the Suicidal Ideation section or "yes" on any item of the Suicidal Behavior section is considered positive. Range is 2-25
Time frame: 12 weeks
Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in Flanker from the NIH-TCB
Flanker Inhibitory control will assess inhibitory control and attention through asking participant to focus on one stimuli will not focusing on any stimuli surrounding it.
Time frame: 12 weeks
Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in Fluid Reasoning Composite Change Sensitive Scores from the NIH-TCB
The Fluid Cognition Composite (FCC) from the NIH Toolbox Cognition Battery (NIHTB-CB) is designed to measure changes to neurological functioning. It combines scores from five tests (Dimensional Change Card Sort, Flanker, List Sorting, Pattern Comparison, and Picture Sequence Memory) to provide a measure of executive function, memory, and processing speed. Higher scores indicate higher level of functioning. Superior ability is 130, average is approx. 100 and less than 70 is impairment.
Time frame: 12 weeks
Phase 3: Change from baseline to week 4 and week 8 in Total Cognition Composite score from the NIH-TCB
The NIH Toolbox (NIH-TCB) Total Cognition Composite Change-Sensitive Score (CSS) is used to measure cognitive change over time. It is calculated by combining the Crystallized Composite (reading/vocabulary) and Fluid Composite (memory/executive function/speed) scores. Higher scores indicate higher level of functioning. The scores typically span across the developmental range, often extending well above and below the 500-point mark depending on the age and cognitive ability of the individual.
Time frame: 8 weeks
Phase 3: The PK parameters of codabakalner concentrations in plasma-Cmax
Maximum concentration of drug in plasma following dose
Time frame: 12 weeks
Phase 3: Change in from baseline to Week 4, Week 8, and Week 12, in ABC total score and subscale scores (FXS scoring)
The Aberrant Behavior Checklist-Community edition (ABC-C) is a 58-item, caregiver-rated symptom checklist for assessing problem behaviors of children and adults with mental retardation at home, in residential facilities, and work training centers. The assessment was done by attributing to each item a score from 0 ("not at all a problem") to 3 ("problem is severe in degree") The ABC will be scored using the FXS-specific factoring system (ABC-FX) for which the total score ranks from 0 to 165.
Time frame: 12 weeks
Phase 3: Change from baseline to Week 4, Week 8, and Week 12 in behaviors and other symptoms on NRS by caregiver
Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'
Time frame: 12 weeks
Phase 3: Change from baseline to Week 12 in Vineland Adaptive Behavior Scale 3rd Edition
Vineland-3 Adaptive Behavior Scale (Vineland-3), using the composite score and domain scores from communication, daily living skills, and socialization. The adaptive behavior composite standard score is computed from the sum of standard scores from the domains and converted into the adaptive behavior composite standard score. Higher scores indicate a higher adaptive level of functioning.
Time frame: 12 weeks
Phase 3: Change from baseline in CGI-S as assessed by investigator
This is a 7-point clinician-rated tool used to measure how ill a patient is at the time of assessment
Time frame: 12 weeks
Phase 3: Change from baseline in CGI-I as assessed by investigator
The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale used to assess treatment response. The score ranges from 1 to 7 (with 1 being "very much improved", 4 being "no change" to 7 being "very much worse")
Time frame: 12 weeks
Phase 3: Change from baseline in Caregiver Global Impression of Improvement (CGI-C) assessments
The Caregiver Global Impression of Improvement (CGI-C) is a global measure to provide a caregiver's perspective of a subject's overall condition. The caregiver will use a 7-point scale to assess how the condition has changed from baseline. A higher number indicates worsening condition.
Time frame: 12 weeks
Phase 3: Change from baseline in the Numerical Rating Scale at Week 4, Week 8, and Week 12 as completed by the caregiver
Numerical rating scale (NRS) scores based on patient-specific behaviors within the domains of Daily Function, Language, and Academic Skill. Caregiver will rate individual from 0 to 10, where 0 indicates 'worst problem' and 10 indicates' no problem at all.'
Time frame: 12 weeks
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Feb 2030, 38 months later.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Dec 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spinogenix